What is it about?
Objective: To determine the rheumatic manifestations associated with hematologic malignancies namely acute and chronic leukemia, Hodgkin’s and non-Hodgkin’s lymphomas, and multiple myeloma; and the markers correlating with their presence. Methods: Eighty patients with hematologic malignancies (28 leukemia, 28 lymphoma and 24 multiple myelomas) were evaluated and examined for the presence of rheumatic manifestations, clinically, radiologically, and by bone scan. Two groups of controls: clinical and laboratory (80 and 15 healthy individuals from the normal population respectively) were also studied. Routine laboratory tests and bone marrow aspiration were done for all patients, while serum rheumatoid factor (RF), antinuclear antibodies (ANA), creatine phosphokinase (CPK), and serum beta-2 macroglobulin were assessed as a marker for rheumatic manifestations in patients and controls. Results: Rheumatic manifestations were identified in 50 patients with hematologic malignancies (62.5%) and 21 clinical controls (26.3%) (p 0.001, odds ratio=4.7, and 95% confidence interval=2.4-9.2). Arthralgia and low back pain were the most significantly rheumatic manifestations associated with hematological malignancies in comparison with healthy controls (OR=15.4, and OR=3.4 respectively). Serum beta-2 macroglobulin was elevated in 38 patients (47.5%), rheumatoid factor was positive in 30 patients (37.5%), and ANA was found in 19 (23.7%) with a significant difference between patients and laboratory controls. 60 patients (75%) had radiological findings and 19 patients (23.75%) had an increased uptake in bone scan. Serum beta-2macroglobulin was positively correlated with rheumatic manifestations (r=0.21, p=0.02), osteopenia in x-rays (r=0.24, p=0.03), and increased uptake in bone scan (r=0.41, p< 0.001).
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Rheumatic signs and symptoms may be the presenting manifestations of the underlying hematologic disease. The clinical findings may mimic those of primary rheumatologic syndromes such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), scleroderma, or systemic vasculitis
Perspectives
rheumatic manifestations occur in 62.5% of patients with hematologic malignancies, significantly more commonly than in age- and sex-matched controls, with an odds ratio of 4.7. Joint pain, bone pain, low back pain and arthritis are the commonest manifestations. Awareness of these rheumatic manifestations is of great importance as some of them may be helpful in early detection of the malignant disease. RF and ANA are not useful diagnostic tests for evaluating those patients, being falsely positive and not discriminating patients with and without rheumatic manifestations. Beta-2 macroglobulin is a useful laboratory test, being a marker for the presence of rheumatic manifestations and predicting osteopenia in x-rays and increased uptake in bone scan.
Professor shereen refaat kamel
Minia University
Read the Original
This page is a summary of: Rheumatic manifestations of hematologic malignancies: Correlation with, Journal of Hematological Malignancies, December 2011, Sciedu Press,
DOI: 10.5430/jhm.v1n1p15.
You can read the full text:
Contributors
The following have contributed to this page
